iwAL 2018 | Checkpoint inhibitors: parallel management of the disease and immune-related toxicities
Naval Daver
• 17 Feb 2018
As our knowledge of immunotherapy increases, so has our understanding of its side effects. In this interview, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the types of immune-related toxicities which are seen in patients with acute myeloid leukemia (AML) who have received immune checkpoint inhibitors. Importantly, Dr Daver highlights the necessity of treating the disease while simultaneously managing any toxicities. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.
